Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Beyer

Showing results (211-220 of 225) with videos related to

Pageof 23
Sort By:
Annals of Internal Medicine|April 2, 2014
Safety and feasibility of a diagnostic algorithm combining clinical probability, d-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis: a prospective management studyAnkie Kleinjan, Marcello Di Nisio, Jan Beyer-Westendorf, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|December 20, 2018
Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trialStefano Barco, Mariaconcetta Russo, Eric Vicaut, et al.
Journal of Thrombosis and Haemostasis : JTH|April 5, 2020
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluationGuy Young, Anthonie W A Lensing, Paul Monagle, et al.
The New England Journal of Medicine|February 8, 2019
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa InhibitorsStuart J Connolly, Mark Crowther, John W Eikelboom, et al.
Journal of Thrombosis and Haemostasis : JTH|June 12, 2024
Risk assessment tools for bleeding in patients with unprovoked venous thromboembolism: an analysis of the PLATO-VTE studyNoori A M Guman, Anne-Marie L Becking, Suzanne S Weijers, et al.
Geburtshilfe Und Frauenheilkunde|February 24, 2021
Hormonal Contraception. Guideline of the DGGG, OEGGG and SGGG (S3 Level, AWMF Registry Number 015/015, January 2020)Sebastian Franik, Rupert Bauersachs, Jan Beyer-Westendorf, et al.
Journal of Thrombosis and Haemostasis : JTH|February 25, 2023
Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort studyFrits I Mulder, Noémie Kraaijpoel, Marc Carrier, et al.
Research and Practice in Thrombosis and Haemostasis|October 1, 2025
Quantitative targeted proteomics for occult cancer screening in patients with unprovoked venous thromboembolism: results from the prospective PLATO-VTE studyNoori A M Guman, Noémie Kraaijpoel, Frits I Mulder, et al.
Research and Practice in Thrombosis and Haemostasis|July 19, 2021
Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarinRoisin Bavalia, Ingrid M Bistervels, Wim G Boersma, et al.
The New England Journal of Medicine|April 11, 2014
Fibrinolysis for patients with intermediate-risk pulmonary embolismGuy Meyer, Eric Vicaut, Thierry Danays, et al.
Pageof 23

Showing results (211-220 of 225) with videos related to

Sort By:
Pageof 23
Annals of Internal Medicine|April 2, 2014
Safety and feasibility of a diagnostic algorithm combining clinical probability, d-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis: a prospective management studyAnkie Kleinjan, Marcello Di Nisio, Jan Beyer-Westendorf, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|December 20, 2018
Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trialStefano Barco, Mariaconcetta Russo, Eric Vicaut, et al.
Journal of Thrombosis and Haemostasis : JTH|April 5, 2020
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluationGuy Young, Anthonie W A Lensing, Paul Monagle, et al.
The New England Journal of Medicine|February 8, 2019
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa InhibitorsStuart J Connolly, Mark Crowther, John W Eikelboom, et al.
Journal of Thrombosis and Haemostasis : JTH|June 12, 2024
Risk assessment tools for bleeding in patients with unprovoked venous thromboembolism: an analysis of the PLATO-VTE studyNoori A M Guman, Anne-Marie L Becking, Suzanne S Weijers, et al.
Geburtshilfe Und Frauenheilkunde|February 24, 2021
Hormonal Contraception. Guideline of the DGGG, OEGGG and SGGG (S3 Level, AWMF Registry Number 015/015, January 2020)Sebastian Franik, Rupert Bauersachs, Jan Beyer-Westendorf, et al.
Journal of Thrombosis and Haemostasis : JTH|February 25, 2023
Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort studyFrits I Mulder, Noémie Kraaijpoel, Marc Carrier, et al.
Research and Practice in Thrombosis and Haemostasis|October 1, 2025
Quantitative targeted proteomics for occult cancer screening in patients with unprovoked venous thromboembolism: results from the prospective PLATO-VTE studyNoori A M Guman, Noémie Kraaijpoel, Frits I Mulder, et al.
Research and Practice in Thrombosis and Haemostasis|July 19, 2021
Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarinRoisin Bavalia, Ingrid M Bistervels, Wim G Boersma, et al.
The New England Journal of Medicine|April 11, 2014
Fibrinolysis for patients with intermediate-risk pulmonary embolismGuy Meyer, Eric Vicaut, Thierry Danays, et al.
Pageof 23